Pharmaceutical Executive
Pharmaceutical Executive
Pharmaceutical Executive Podcast
The Weight-Loss Gold Rush: Legal and Regulatory Implications
17 minutes Posted Jul 11, 2024 at 10:00 am.
0:00
17:10
Download MP3
Show notes
Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.